Cell line · CVCL_0463
NCI-H157
Cancer cell line, Homo sapiens. Lung squamous cell carcinoma. Cellosaurus records it as contaminated. 40 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H157. Cell lines, record CVCL_0463. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0463
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H157
- Accession
- CVCL_0463
- RRID
- RRID:CVCL_0463
- Synonyms
- NCl-H157, NCI H157, H157, H-157, NCI-157, NCIH157DM, H157DM
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 59Y
- Category
- Cancer cell line
- Diseases
- Lung squamous cell carcinoma (NCIt C3493)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems1
| Problem | Cellosaurus's note |
|---|---|
| Contaminated | NCI-H157 and NCI-H1264 have been shown to be identical. |
Source Cellosaurus
Papers40
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NAPRT loss promotes lung tumor initiation and growth through AKT signaling independently of NAD+ biosynthesis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. | J Biol Chem | 2026 | Its Methods give the RRID and name the line | PubMed | |
| JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. | Clin Cancer Res | 2024 | Cellosaurus cites it | PubMed | |
| TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Identification and Target-Modification of SL-BBI: A Novel Bowman-Birk Type Trypsin Inhibitor from Sylvirana latouchii. | Biomolecules | 2020 | Its Methods give the RRID and name the line | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Discovery and Rational Design of a Novel Bowman-Birk Related Protease Inhibitor. | Biomolecules | 2019 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 40
See all 40 papersRelatives3
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | H157R | CVCL_VD88 | Has a recorded problem | Cell lines |
| Derived from it | HyCyte NCI-H157-Luc | CVCL_E3I3 | Has a recorded problem | Cell lines |
| From the same person | NCI-H1264 | CVCL_3970 | Has a recorded problem | Cell lines |
Cell banks5
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5802 | Discontinued | Cellosaurus |
| CLS | 300387 | CLS | |
| Hysigen | TCH-C431 | Hysigen | |
| KCB | KCB 200814YJ | Cellosaurus | |
| KCLB | 90157 | Discontinued | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0463
GET https://conductscience.org/api/cell-lines/v1/CVCL_0463/papers?page=2